| Document and Entity Information | May 11, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Description | On May 11, 2022, Acorda Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K to report, among other things, its financial performance for the first quarter of 2022 (the “Original 8-K”). This amendment is being filed by the Company solely for the purpose of updating the Original 8-K as further described below. |
| Amendment Flag | true |
| Document Period End Date | May 11, 2022 |
| Entity Registrant Name | Acorda Therapeutics, Inc. |
| Entity Central Index Key | 0001008848 |
| Entity Emerging Growth Company | false |
| Entity File Number | 001-31938 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 13-3831168 |
| Entity Address, Address Line One | 420 Saw Mill River Road |
| Entity Address, City or Town | Ardsley |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10502 |
| City Area Code | (914) |
| Local Phone Number | 347-4300 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of each class | Common Stock $0.001 par value per share |
| Trading Symbol | ACOR |
| Name of each exchange on which registered | NASDAQ |
